Guideline review: EASL clinical practice guidelines: drug-induced liver injury (DILI).
| Autor: | Brennan PN; Centre for Regenerative Medicine, The University of Edinburgh Edinburgh Medical School, Edinburgh, UK.; Molecular and Clinical Medicine, University of Dundee School of Medicine, Dundee, UK., Cartlidge P; Department of Gastroenterology, Ninewells Hospital and Medical School, NHS Tayside, Dundee, UK., Manship T; Centre for Liver and Digestive Disorders, NHS Lothian, Edinburgh, UK., Dillon JF; Department of Gastroenterology, Ninewells Hospital and Medical School, NHS Tayside, Dundee, UK.; Molecular and Clinical Medicine, University of Dundee College of Medicine Dentistry and Nursing, Dundee, UK. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Frontline gastroenterology [Frontline Gastroenterol] 2021 Jul 29; Vol. 13 (4), pp. 332-336. Date of Electronic Publication: 2021 Jul 29 (Print Publication: 2022). |
| DOI: | 10.1136/flgastro-2021-101886 |
| Abstrakt: | The European Association for the Study of the Liver has produced extensive guidelines for the investigation and management of drug-induced liver injury. Here, we provide a commentary and overview of some of the principle disease investigations and management that arise from these guideline recommendations. Competing Interests: Competing interests: JFD has received research grants and lecture honoraria from MSD, Abbvie and Gilead. (© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|